Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on October 14, 2002

Hypertension. 2002
Published online before print October 14, 2002, doi: 10.1161/01.HYP.0000037979.53963.8F
A more recent version of this article appeared on December 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/6/847    most recent
01.HYP.0000037979.53963.8Fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiemer, G.
Right arrow Articles by Heitsch, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiemer, G.
Right arrow Articles by Heitsch, H.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Endothelium/vascular type/nitric oxide

AVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1-7) on the Endothelium

Gabriele Wiemer; Lawrence W. Dobrucki; Febee R. Louka; Tadeusz Malinski; and Holger Heitsch*

From DG Cardiovascular Diseases/Medicinal Chemistry, Aventis Pharma Deutschland GmbH (G.W., H.H.), Frankfurt/Main, Germany; and the Department of Chemistry and Biochemistry, Ohio University (L.W.D., F.R.L., T.M.), Athens, Ohio.

* To whom correspondence should be addressed. E-mail: holger.heitsch{at}aventis.com.

Abstract—Recently, we demonstrated that the heptapeptide angiotensin-(1-7) (Ang-[1-7]) exhibits a favorable kinetic of nitric oxide (NO) release accompanied by extremely low superoxide (O2-) production. In this report we describe AVE 0991, a novel nonpeptide compound that evoked effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) competed for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 values of 21±35 and 220±280 nmol/L, respectively. Stimulated NO and O2- release from bovine aortic endothelial cells was directly and simultaneously measured on the cell surface by selective electrochemical nanosensors. Peak concentrations of NO and O2- release by AVE 0991 and Ang-(1-7) (both 10 µmol/L) were not significantly different (NO: 295±20 and 270±25 nmol/L; O2-: 18±2 and 20±4 nmol/L). However, the released amount of bioactive NO was {approx}5 times higher for AVE 0991 in comparison to Ang-(1-7). The selective Ang-(1-7) antagonist [D-Ala7]-Ang-(1-7) inhibited the AVE 0991-induced NO and O2- production by {approx}50%. A similar inhibition level was observed for the Ang II AT1 receptor antagonist EXP 3174. In contrast, the Ang II AT2 receptor antagonist PD 123,177 inhibited the AVE 0991-stimulated NO production by {approx}90% but without any inhibitory effect on O2- production. Both NO and O2- production were inhibited by NO synthase inhibition ({approx}70%) and by bradykinin B2 receptor blockade ({approx}80%). AVE 0991 efficiently mimics the effects of Ang-(1-7) on the endothelium, most probably through stimulation of a specific, endothelial Ang-(1-7)-sensitive binding site causing kinin-mediated activation of endothelial NO synthase.


Key words: nitric oxide synthase • endothelium • angiotensin • nitric oxide




This article has been cited by other articles:


Home page
HypertensionHome page
M. B.L. Carvalho, F. V. Duarte, R. Faria-Silva, B. Fauler, L. T. da Mata Machado, R. D. de Paula, M. J. Campagnole-Santos, and R. A.S. Santos
Evidence for Mas-Mediated Bradykinin Potentiation by the Angiotensin-(1-7) Nonpeptide Mimic AVE 0991 in Normotensive Rats
Hypertension, October 1, 2007; 50(4): 762 - 767.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Faria-Silva, F. V. Duarte, and R. A.S. Santos
Short-Term Angiotensin(1-7) Receptor Mas Stimulation Improves Endothelial Function in Normotensive Rats
Hypertension, October 1, 2005; 46(4): 948 - 952.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. V. B. Pinheiro, A. C. Simoes e Silva, W. O. Sampaio, R. D. de Paula, E. P. Mendes, E. D. Bontempo, J. B. Pesquero, T. Walther, N. Alenina, M. Bader, et al.
Nonpeptide AVE 0991 Is an Angiotensin-(1-7) Receptor Mas Agonist in the Mouse Kidney
Hypertension, October 1, 2004; 44(4): 490 - 496.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. A.S. Santos, A. S. Haibara, M. J. Campagnole-Santos, A. C. Simoes e Silva, R. D. Paula, S. V.B. Pinheiro, M. de Fatima Leite, V. S. Lemos, D. M.R. Silva, M. T. Guerra, et al.
Characterization of a New Selective Antagonist for Angiotensin-(1-7), D-Pro7-Angiotensin-(1-7)
Hypertension, March 1, 2003; 41(3): 737 - 743.
[Abstract] [Full Text] [PDF]